Zomig gets Japanese approval
AstraZeneca has received approval to market the migraine treatment Zomig in Japan. Since its launch in the US in 1997, Zomig has been marketed in more than 50 countries, with worldwide sales of US$237m last year, an increase of 25% on 1999.